{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:16:08Z","timestamp":1790615768428,"version":"4.1.0"},"reference-count":76,"publisher":"Informa UK Limited","issue":"7","funder":[{"DOI":"10.13039\/501100007494","name":"Fondation Plan Alzheimer","doi-asserted-by":"publisher","award":["AAP2015 Project TRIAD 016"],"award-info":[{"award-number":["AAP2015 Project TRIAD 016"]}],"id":[{"id":"10.13039\/501100007494","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/french","name":"French Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ADAMGUARD ANR-12-BSV4-008-01"],"award-info":[{"award-number":["ADAMGUARD ANR-12-BSV4-008-01"]}],"id":[{"id":"10.13039\/french","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/french","name":"French Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["MALAD ANR-12-JS007-0012-01"],"award-info":[{"award-number":["MALAD ANR-12-JS007-0012-01"]}],"id":[{"id":"10.13039\/french","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2020,7,2]]},"DOI":"10.1080\/13543776.2020.1767587","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T08:14:45Z","timestamp":1589357685000},"page":"495-508","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":20,"title":["Therapeutic modulators of the serotonin 5-HT\n                    <sub>4<\/sub>\n                    receptor: a patent review (2014-present)"],"prefix":"10.1080","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5814-3173","authenticated-orcid":false,"given":"Caroline","family":"Lanthier","sequence":"first","affiliation":[{"name":"Normandie Univ, UNICAEN, CERMN (Centre d\u2019Etudes et de Recherche sur le M\u00e9dicament de Normandie)","place":["F-14032 Caen, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-615X","authenticated-orcid":false,"given":"Patrick","family":"Dallemagne","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNICAEN, CERMN (Centre d\u2019Etudes et de Recherche sur le M\u00e9dicament de Normandie)","place":["F-14032 Caen, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4725-7738","authenticated-orcid":false,"given":"C\u00e9dric","family":"Lecoutey","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNICAEN, CERMN (Centre d\u2019Etudes et de Recherche sur le M\u00e9dicament de Normandie)","place":["F-14032 Caen, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0576-5518","authenticated-orcid":false,"given":"Sylvie","family":"Claeysen","sequence":"additional","affiliation":[{"name":"CNRS, INSERM","place":["Montpellier, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7996-2082","authenticated-orcid":false,"given":"Christophe","family":"Rochais","sequence":"additional","affiliation":[{"name":"Normandie Univ, UNICAEN, CERMN (Centre d\u2019Etudes et de Recherche sur le M\u00e9dicament de Normandie)","place":["F-14032 Caen, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,6,18]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-895X(25)10130-2"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2008.05.013"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2013.03.060"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/156802610791111551"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.08102FP"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2004.40.12.872576"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/1074248409360357"},{"key":"e_1_3_4_10_1","unstructured":"In Brief: tegaserod (Zelnorm) returns. Med Lett Drugs Ther. 2019;61(1571):72. PMID: 31169806."},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.244079"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.778"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(00)89081-1"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb13303.x"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199406020-00018"},{"key":"e_1_3_4_16_1","doi-asserted-by":"crossref","unstructured":"Kilbinger H Wolf D. Effects of 5-HT4 receptor stimulation on basal and electrically evoked release of acetylcholine from Guinea-Pig Myenteric Plexus. Naunyn Schmiedebergs Arch Pharmacol. 1992;345(3):270\u2013275. .","DOI":"10.1007\/BF00168686"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0953-816x.2000.01453.x"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb15154.x"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb15309.x"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2007.02.001"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm801327q"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2006.07.021"},{"key":"e_1_3_4_23_1","doi-asserted-by":"crossref","unstructured":"Lelong V Lhonneur L Dauphin F et al. BIMU 1 and RS 67333 two 5-HT4 receptor agonists modulate spontaneous alternation deficits induced by scopolamine in the mouse. Naunyn Schmiedebergs Arch Pharmacol. 2003;367(6):621\u2013628.","DOI":"10.1007\/s00210-003-0743-2"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.034249"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2007.06.016"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/1073858414561303"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyu034"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291720000604"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291719002836"},{"key":"e_1_3_4_30_1","unstructured":"Ishii T Kinoshita K. Therapeutic agent for cognitive dysfunction accompanying parkinson disease. JP2018168072A November 1 2018."},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S64621"},{"key":"e_1_3_4_32_1","unstructured":"Selective 5-HT4 receptor agonist and Proton Pump Inhibitor (PPI) in subjects with Gastroesophageal Reflux Disease (GERD) - full text view. ClinicalTrials.gov; [cited 2020 Mar 9]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01472939"},{"key":"e_1_3_4_33_1","unstructured":"Maeyer JHD Schuurkes JAJ. Pro-cognitive compound. WO2014083003A1 June 5 2014."},{"key":"e_1_3_4_34_1","unstructured":"Takahashi N Yamamoto T Shimada K et al. 5-HT4 receptor agonist for gastroparesis. WO2015174098A1 November 19 2015."},{"key":"e_1_3_4_35_1","unstructured":"Takahashi N. 5-HT4 receptor agonist as a prokinetic agent. US20140051726A1 February 20 2014."},{"key":"e_1_3_4_36_1","unstructured":"Numata T Sudo M Sun X. Benzisoxazole derivative salt. WO2015178020A1 November 26 2015."},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.4236\/aad.2013.23012"},{"key":"e_1_3_4_38_1","unstructured":"Noguchi H Waizumi N. (R)-4-((4-((4-(Tetrahydrofuran-3-Yloxy)Benzo[d]Isoxazol-3-Yloxy)Methyl)Piperidin-1-Yl)Methyl)Tetrahydro-2h-Pyran-4-Ol a Partial Agonist of 5-HT4 Receptors. WO2011101774A1 August 25 2011."},{"key":"e_1_3_4_39_1","unstructured":"Alisi MA Cazzolla N Costi R et al. Compound with serotoninergic activity process for preparing it and pharmaceutical composition comprising it. US8686147B2 April 1 2014."},{"key":"e_1_3_4_40_1","unstructured":"Guglielmotti A Polenzani L Alisi A et al. Use of indazole derivatives for the treatment of neuropathic pain. US7638534B2 December 29 2009."},{"key":"e_1_3_4_41_1","unstructured":"Dhanoa DS. Deuterium-enriched pyridinonecarboxamides and derivatives. US20150080377A1 March 19 2015."},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2014.943184"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.192351"},{"key":"e_1_3_4_44_1","unstructured":"Mikami S Uematsu M. Agent for preventing or treating agent bovine gastrointestinal disease by mosapride citrate. JP2017014113A January 19 2017."},{"key":"e_1_3_4_45_1","unstructured":"Kim SH Im WB Choi SH et al. Benzamide derivatives. US9221790B2 December 29 2015."},{"key":"e_1_3_4_46_1","unstructured":"Dallemagne P Rochais C Lecoutey C et al. Composes inhibiteurs de l\u2019acetylcholinesterase et agonistes des recepteurs serotoninergiques 5ht4 a effet promnesiant leurs procedes de preparation et compositions pharmaceutiques les contenant. WO2014195593A2 December 11 2014."},{"key":"e_1_3_4_47_1","unstructured":"Cheng L Riggs-Sauthier J Anand NK. Oligomer-containing benzamide-based compounds. WO2014043707A1 March 20 2014."},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(96)00230-5"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm300953p"},{"key":"e_1_3_4_50_1","unstructured":"Ohshiro H Fujiuchi A Take Y. 5-HT4 receptor agonists for the treatment of dementia. US8980922B2 March 17 2015."},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21-02-00372.2001"},{"key":"e_1_3_4_52_1","unstructured":"Ikeda J Nakamura T Otaka H. Oxadiazole derivative and pharmaceutical use of same. WO2014092104A1 June 19 2014."},{"key":"e_1_3_4_53_1","unstructured":"Nirogi R Mohammed AR Shinde AK et al. Indazole compounds as 5-HT4 receptor agonists. WO2015092804A1 June 25 2015."},{"key":"e_1_3_4_54_1","unstructured":"Nirogi R Mohammed AR Yarlagadda S et al. Heteroaryl compounds as 5-HT4 receptor ligands. US9079894B2 July 14 2015."},{"key":"e_1_3_4_55_1","unstructured":"Nirogi R Mohammed AR Jasti V. Process for large scale production of 1-Isopropyl-3-{5- [1-(3-Methoxypropyl) Piperidin-4-Yl]-[1 3 4]Oxadiazol-2-Yl}- 1h-Indazole Oxalate. WO2016027277A1 February 25 2016."},{"key":"e_1_3_4_56_1","unstructured":"Nirogi R Shinde AK Mohammed AR et al. Amide compounds as 5-HT4 receptor agonists. WO2016128990A1 August 18 2016."},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1410315111"},{"key":"e_1_3_4_58_1","unstructured":"Suzuki T Imanishi N Itahana H et al. Novel benzamide derivative and medicinal composition containing the same. WO1995018104A1 July 6 1995."},{"key":"e_1_3_4_59_1","unstructured":"Takadoi M Kobayashi F Sekiguchi H. Novel benzamide derivatives. WO1997010207A1 March 20 1997."},{"key":"e_1_3_4_60_1","unstructured":"Nirogi R Shinde AK Jasti V. 5-Amino-Quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists. WO2014147636A1 September 25 2014."},{"key":"e_1_3_4_61_1","doi-asserted-by":"crossref","unstructured":"Iwanaga Y Miyashita N Mizutani F et al. Stimulatory effect of N-[4-[2-(Dimethylamino)-Ethoxy]Benzyl]-3 4-dimethoxybenzamide hydrochloride (HSR-803) on normal and delayed gastrointestinal propulsion. Jpn J Pharmacol. 1991;56(3):261\u2013269.","DOI":"10.1016\/S0021-5198(19)39852-X"},{"key":"e_1_3_4_62_1","unstructured":"Sim JY Cha MH Yoon YA et al. Bicyclic derivative containing pyrimidine ring and preparation method therefor. WO2014189331A1 November 27 2014."},{"key":"e_1_3_4_63_1","unstructured":"Khoo JH Lee DB Lee JS et al. Novel processes for preparing a diaminopyrimidine derivative or acid addition salt thereof. WO2019221522A1 November 21 2019."},{"key":"e_1_3_4_64_1","unstructured":"Ahn KK Cha MH Jung EJ et al. Diaminopyrimidine derivatives and processes for the preparation thereof. WO2012115480A2 August 30 2012."},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13094"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59805-7"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00457"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14964"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2013.00096"},{"key":"e_1_3_4_70_1","doi-asserted-by":"crossref","unstructured":"Dileep Kumar JS John Mann J. PET tracers for serotonin receptors and their applications. Cent Nerv Syst Agents Med Chem. 2014;14(2):96\u2013112.","DOI":"10.2174\/1871524914666141030124316"},{"issue":"5","key":"e_1_3_4_71_1","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S0026-895X(24)23188-6","article-title":"Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain","volume":"55","author":"Claeysen S","year":"1999","unstructured":"Claeysen S, Sebben M, Becamel C, et al. Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. Mol Pharmacol. 1999;55(5):910\u2013920.","journal-title":"Mol Pharmacol"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2011.01.012"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145711000782"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nlm.2016.06.014"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2012.02.012"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2016.05.048"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111596"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00148"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2020.1767587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:30:42Z","timestamp":1772767842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2020.1767587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":76,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,2]]}},"alternative-id":["10.1080\/13543776.2020.1767587"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2020.1767587","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-03-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}